Alagille Syndrome Follow-up

1. Krantz ID, Piccoli DA, Spinner NB. Alagille syndrome. J Med Genet. 1997 Feb. 34(2):152-7. [QxMD MEDLINE Link].

2. Watson GH, Miller V. Arteriohepatic dysplasia: familial pulmonary arterial stenosis with neonatal liver disease. Arch Dis Child. 1973 Jun. 48(6):459-66. [QxMD MEDLINE Link].

3. Alagille D, Odievre M, Gautier M, Dommergues JP. Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur. J Pediatr. 1975 Jan. 86(1):63-71. [QxMD MEDLINE Link].

4. McDaniell R, Warthen DM, Sanchez-Lara PA, et al. NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet. 2006 Jul. 79(1):169-73. [QxMD MEDLINE Link].

5. Li L, Krantz ID, Deng Y, et al. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet. 1997 Jul. 16(3):243-51. [QxMD MEDLINE Link].

6. Krantz ID, Colliton RP, Genin A, et al. Spectrum and frequency of jagged1 (JAG1) mutations in Alagille syndrome patients and their families. Am J Hum Genet. 1998 Jun. 62(6):1361-9. [QxMD MEDLINE Link].

7. Sparks EE, Huppert KA, Brown MA, Washington MK, Huppert SS. Notch signaling regulates formation of the three-dimensional architecture of intrahepatic bile ducts in mice. Hepatology. 2010 Apr. 51 (4):1391-400. [QxMD MEDLINE Link].

8. Bucuvalas JC, Horn JA, Carlsson L, et al. Growth hormone insensitivity associated with elevated circulating growth hormone-binding protein in children with Alagille syndrome and short stature. J Clin Endocrinol Metab. 1993 Jun. 76(6):1477-82. [QxMD MEDLINE Link].

9. Hingorani M, Nischal KK, Davies A, et al. Ocular abnormalities in Alagille syndrome. Ophthalmology. 1999 Feb. 106(2):330-7. [QxMD MEDLINE Link].

10. Emerick KM, Rand EB, Goldmuntz E, et al. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology. 1999 Mar. 29(3):822-9. [QxMD MEDLINE Link].

11. Rock NM, Demaret T, Stéphenne X, et al. Intracranial hypertension and papilledema in a large cohort of pediatric patients with Alagille syndrome. J Pediatr Gastroenterol Nutr. 2020 Nov. 71 (5):655-62. [QxMD MEDLINE Link].

12. Lalani SR, Thakuria JV, Cox GF, Wang X, Bi W, Bray MS. 20p12.3 microdeletion predisposes to Wolff-Parkinson-White syndrome with variable neurocognitive deficits. J Med Genet. 2009 Mar. 46(3):168-75. [QxMD MEDLINE Link]. [Full Text].

13. Kamath BM, Podkameni G, Hutchinson AL, et al. Renal anomalies in Alagille syndrome: a disease-defining feature. Am J Med Genet A. 2012 Jan. 158A (1):85-9. [QxMD MEDLINE Link].

14. Kamath BM, Spinner NB, Rosenblum ND. Renal involvement and the role of Notch signalling in Alagille syndrome. Nat Rev Nephrol. 2013. 9:409-18. [QxMD MEDLINE Link].

15. Kamath BM, Spinner NB, Emmerich KM, et al. Vascular anomalies in Alagille syndrome: a significant cause of morbidity and mortality. Circulation. 2004. 110:1354-8. [QxMD MEDLINE Link]. [Full Text].

16. Mouzaki M, Bass LM, Sokol RJ, et al. Early life predictive markers of liver disease outcome in an International, Multicentre Cohort of children with Alagille syndrome. Liver Int. 2016 May. 36 (5):755-60. [QxMD MEDLINE Link].

17. Cynamon HA, Andres JM, Iafrate RP. Rifampin relieves pruritus in children with cholestatic liver disease. Gastroenterology. 1990 Apr. 98(4):1013-6. [QxMD MEDLINE Link].

18. Livmarli (maralixibat) [package insert]. Foster City, CA: Mirum Pharmaceuticals. September 2021. Available at [Full Text].

19. Ovchinsky N. Efficacy and Safety of Odevixibat in Patients with Alagille Syndrome: Top-line Results from Assert, A Phase III, Double-blind, Randomized, Placebo-controlled Study (abstract). Presented at the American Association for Study of Liver Diseases (AASLD) The Liver Meeting 2022. Washington, DC. 2022 Nov 7. [Full Text].

20. Bylvay (odevixibat) [package insert]. Boston, MA: Ipsen Pharmaceuticals & Albireo Pharma, Inc. June 2023. Available at [Full Text].

21. Kasahara M, Kiuchi T, Inomata Y, et al. Living-related liver transplantation for Alagille syndrome. Transplantation. 2003 Jun 27. 75(12):2147-50. [QxMD MEDLINE Link].

22. Whitington PF, Whitington GL. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology. 1988 Jul. 95(1):130-6. [QxMD MEDLINE Link].

23. [Guideline] Murray KF, Carithers RL Jr. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005 Jun. 41(6):1407-32. [QxMD MEDLINE Link]. [Full Text].

24. Arnon R, Annunziato R, Miloh T, et al. Orthotopic liver transplantation for children with Alagille syndrome. Pediatr Transplant. 2010 Aug. 14 (5):622-8. [QxMD MEDLINE Link].

25. Bekassy AN, Garwicz S, Wiebe T, et al. Hepatocellular carcinoma associated with arteriohepatic dysplasia in a 4-year-old girl. Med Pediatr Oncol. 1992. 20(1):78-83. [QxMD MEDLINE Link].

26. Danks DM, Campbell PE, Jack I, et al. Studies of the aetiology of neonatal hepatitis and biliary atresia. Arch Dis Child. 1977 May. 52(5):360-7. [QxMD MEDLINE Link].

27. Gottrand F, Clavey V, Fruchart JC, Farriaux JP. Lipoprotein pattern and plasma lecithin cholesterol acyl transferase activity in children with Alagille syndrome. Atherosclerosis. 1995 Jun. 115(2):233-41. [QxMD MEDLINE Link].

28. Hoffenberg EJ, Narkewicz MR, Sondheimer JM, et al. Outcome of syndromic paucity of interlobular bile ducts (Alagille syndrome) with onset of cholestasis in infancy. J Pediatr. 1995 Aug. 127(2):220-4. [QxMD MEDLINE Link].

29. Kay MH, Wyllie R, Steffen RM. Use of ursodeoxycholic acid in the treatment of arteriohepatic dysplasia. Clin Pediatr (Phila). 1996 Nov. 35(11):593-6. [QxMD MEDLINE Link].

30. Martin SR, Garel L, Alvarez F. Alagille's syndrome associated with cystic renal disease. Arch Dis Child. 1996 Mar. 74(3):232-5. [QxMD MEDLINE Link].

31. Miguet JP, Mavier P, Soussy CJ, Dhumeaux D. Induction of hepatic microsomal enzymes after brief administration of rifampicin in man. Gastroenterology. 1977 May. 72(5 Pt 1):924-6. [QxMD MEDLINE Link].

32. Oestreich AE, Sokol RJ, Suchy FJ, Heubi JE. Renal abnormalities in arteriohepatic dysplasia and nonsyndromic intrahepatic biliary hypoplasia. Ann Radiol (Paris). 1983 Feb-Mar. 26(2-3):203-9. [QxMD MEDLINE Link].

33. Quiros-Tejeira RE, Ament ME, Heyman MB, et al. Variable morbidity in alagille syndrome: a review of 43 cases. J Pediatr Gastroenterol Nutr. 1999 Oct. 29(4):431-7. [QxMD MEDLINE Link].

34. Rabinovitz M, Imperial JC, Schade RR, Van Thiel DH. Hepatocellular carcinoma in Alagille's syndrome: a family study. J Pediatr Gastroenterol Nutr. 1989 Jan. 8(1):26-30. [QxMD MEDLINE Link].

35. Russo PA, Ellis D, Hashida Y. Renal histopathology in Alagille's syndrome. Pediatr Pathol. 1987. 7(5-6):557-68. [QxMD MEDLINE Link].

36. Shulman SA, Hyams JS, Gunta R. Arteriohepatic dysplasia (Alagille syndrome): extreme variability among affected family members. Am J Med Genet. 1984 Oct. 19(2):325-32. [QxMD MEDLINE Link].

37. Kamath BM, Chen Z, Romero R, et al. Quality of Life and Its Determinants in a Multicenter Cohort of Children with Alagille Syndrome. J Pediatr. 2015 Aug. 167 (2):390-6.e3. [QxMD MEDLINE Link].

Ann Scheimann, MD, MBA Professor, Department of Pediatrics, Section of Nutrition and Gastroenterology, Baylor College of Medicine and Johns Hopkins Medical Institution

Ann Scheimann, MD, MBA is a member of the following medical societies: North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

Disclosure: Received research grant from: prior funding from Millendo, Insys Therapeutics, Zafgen, Saniona, Radius; current funding from Foundation for Prader-Willi Research, Harmony Biosciences, Acadia Pharmaceuticals.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Carmen Cuffari, MD Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine

Carmen Cuffari, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, Royal College of Physicians and Surgeons of Canada

Disclosure: Received honoraria from Prometheus Laboratories for speaking and teaching; Received honoraria from Abbott Nutritionals for speaking and teaching. for: Abbott Nutritional, Abbvie, speakers' bureau.

Robert Baldassano, MD Director, Center for Pediatric Inflammatory Bowel Disease, Children's Hospital of Philadelphia; Professor, Department of Pediatrics, Division of Gastroenterology and Nutrition, University of Pennsylvania School of Medicine

Robert Baldassano, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

Disclosure: Received consulting fee from Abbott, Inc for consulting.

• Print this section
• Print the entire contents of
• Print the entire contents of article